Torcetrapib: Difference between revisions
imported>David E. Volk mNo edit summary |
imported>David E. Volk m (refs) |
||
| Line 18: | Line 18: | ||
== Chemistry == | == Chemistry == | ||
The chemical name of torcetrapib is (2R,4S)-4-[(3,5-Bis-trifluoromethylbenzyl)methoxycarbonylamino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester. The drug has a formula weight of 600.47 g/mol and is registered under the CAS number 262352-17-0. | The chemical name of torcetrapib is (2R,4S)-4-[(3,5-Bis-trifluoromethylbenzyl)methoxycarbonylamino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester. The drug has a formula weight of 600.47 g/mol and is registered under the CAS number 262352-17-0. | ||
== References == | |||
<references/> | |||
Revision as of 10:23, 26 November 2010
|
| |||||||
| torcetrapib | |||||||
| |||||||
| Uses: | cardiac medication | ||||||
| Properties: | |||||||
| Hazards: | increased death and cardiac events | ||||||
| |||||||
Torcetrapib was a drug in development to be used to modulate cholesterol levels by its inhibition of cholesteryl ester transferase protein (CETP). Pfizer announces its withdrawal of torcetrapib from development[1] Although torcetrapib quickly raised HDL cholesterol in the ILLUMINATE study, patients receiving both torcetrapib and atorvastatin has increased incidence of adverse cardiac events and death compared to the control group only receiving atorvastatin. Similar medications include anacetrapib and dalcetrapib.
Chemistry
The chemical name of torcetrapib is (2R,4S)-4-[(3,5-Bis-trifluoromethylbenzyl)methoxycarbonylamino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester. The drug has a formula weight of 600.47 g/mol and is registered under the CAS number 262352-17-0.